Sutpirat Moonmuang
Overview
Explore the profile of Sutpirat Moonmuang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orrapin S, Moonmuang S, Udomruk S, Yongpitakwattana P, Pruksakorn D, Chaiyawat P
Front Immunol
. 2024 Oct;
15:1394284.
PMID: 39359731
Osteosarcoma has a unique tumor microenvironment (TME), which is characterized as a complex microenvironment comprising of bone cells, immune cells, stromal cells, and heterogeneous vascular structures. These elements are intricately...
2.
Thongkumkoon P, Sangphukieo A, Tongjai S, Noisagul P, Sangkhathat S, Laochareonsuk W, et al.
Sci Rep
. 2024 Sep;
14(1):21092.
PMID: 39256458
No abstract available.
3.
Thongkumkoon P, Sangphukieo A, Tongjai S, Noisagul P, Sangkhathat S, Laochareonsuk W, et al.
Sci Rep
. 2024 May;
14(1):11056.
PMID: 38744935
Osteosarcoma is the most common malignant bone cancer in pediatric patients. Patients who respond poorly to chemotherapy experience worse clinical outcomes with a high mortality rate. The major challenge is...
4.
Orrapin S, Thongkumkoon P, Udomruk S, Moonmuang S, Sutthitthasakul S, Yongpitakwattana P, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569711
Circulating tumor cells (CTCs) hold unique biological characteristics that directly involve them in hematogenous dissemination. Studying CTCs systematically is technically challenging due to their extreme rarity and heterogeneity and the...
5.
Moonmuang S, Tantraworasin A, Orrapin S, Udomruk S, Chewaskulyong B, Pruksakorn D, et al.
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902280
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded several significant benefits for lung cancer patients,...
6.
Udomruk S, Phanphaisarn A, Kanthawang T, Sangphukieo A, Sutthitthasakul S, Tongjai S, et al.
Clin Cancer Res
. 2023 Feb;
29(11):2085-2094.
PMID: 36735493
Purpose: Cell-free DNA (cfDNA) analysis is a powerful tool for noninvasively predicting patient outcomes. We analyzed the size distribution of cfDNA and assessed its prognostic and diagnostic values in an...
7.
Klangjorhor J, Pongnikorn D, Sittiju P, Phanphaisarn A, Chaiyawat P, Teeyakasem P, et al.
Sci Rep
. 2022 Jul;
12(1):12824.
PMID: 35896585
This study aimed to analyze burden of STS and GIST in population and survival rate which represented the current situation of treatment in Thailand. The data was collected from five...
8.
Orrapin S, Udomruk S, Lapisatepun W, Moonmuang S, Phanphaisarn A, Phinyo P, et al.
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884432
Circulating tumor cells (CTCs) play a key role in hematogenous metastasis and post-surgery recurrence. In hepatocellular carcinoma (HCC), CTCs have emerged as a valuable source of therapeutically relevant information. Certain...
9.
Moonmuang S, Maniratanachote R, Chetprayoon P, Sornsuwan K, Thongkum W, Chupradit K, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458554
A designed repeat scaffold protein (Ank1D4) recognizing the human immunodeficiency virus-1 (HIV-1) capsid (CA) was formerly established with antiviral assembly. Here, we investigated the molecular mechanism of Ank1D4 function during...
10.
Lo Piccolo L, Jantrapirom S, Moonmuang S, Teeyakasem P, Pasena A, Suksakit P, et al.
Trop Med Int Health
. 2021 Sep;
26(11):1401-1410.
PMID: 34478609
Objective: Germline mutations of the TP53 tumour suppressor gene are the only known cause of the hereditary autosomal disorder called Li-Fraumeni syndrome (LFS). However, little information is available about TP53...